Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00457977 · ClinicalTrials.gov registry record · Phase 3
Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 3
- Development phase
- 181
- Enrollment target
NCT00457977: Completed Phase 3 study, sponsored by University of Minnesota.
NCT00457977 is a Phase 3 study that has completed, run by University of Minnesota. The registered enrollment target is 181 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00457977, a Phase 3 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 181 participants
- Enrollment target
Study Summary
Pneumococcal disease is a serious bacterial infection that can affect different parts of the body, including the lungs. People with chronic illnesses, such as chronic obstructive pulmonary disease (COPD), have a greater risk of developing pneumonia and meningitis as a result of pneumococcal disease. This study will compare the immune response to two types of pneumococcal vaccines in adults with COPD.
Primary Outcome
Opsonophagocytosis activity (OPK) serotype specific geometric means
Interventions
- BIOLOGICAL Pneumovax (PPSV23)
- BIOLOGICAL Prevnar (PCV7)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2007-03 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
What the finished NCT00457977 record still lists
NCT00457977 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Pneumovax (PPSV23) is the first listed.
NCT00457977 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00457977 about?
NCT00457977 is a clinical study titled "Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease". Pneumococcal disease is a serious bacterial infection that can affect different parts of the body, including the lungs. People with chronic illnesses, such as chronic obstructive pulmonary disease (COPD), have a greater risk of developing pneumonia and meningitis as a result of pneumococcal disease....
What is the current status of trial NCT00457977?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 181 participants. The study started on 2007-03. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00457977?
The interventions under investigation include: Pneumovax (PPSV23) (BIOLOGICAL), Prevnar (PCV7) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00457977?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00457977's enrollment target sits among peer trials
181 1422nd of 2000 higher than 579 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia